The potential of precision medicine in allergy and asthma has only started to be explored. A significant clarification in the pathophysiology of rhinitis, chronic rhinosinusitis, asthma, food allergy and drug hypersensitivity was made in the last decade.
| INTRODUCTION
Precision medicine for allergic diseases requires a deep understanding of immunopathology and phenotype heterogeneity in relation to clinically significant outcomes. 1 Precision medicine could also help to limit the socio-economic burden imposed by allergic and chronic respiratory diseases. 2 The implementation of precision medicine demands measurable indicators of biological conditions usually termed biomarkers. A valid biomarker should be quantifiable in an analytical system with well-defined performance and need to be supported by a body of evidence which sufficiently clarifies the pathological and clinical significance of the test results. 4 Moreover, the identification of novel biomarkers applicable in daily practice requires clear clinical models with well-established extreme phenotypes, allowing a better understanding of the disease progression along its severity. Another aspect influencing the clinical applicability is the biological matrix ("sample type") where biomarkers are measured (Table 1) . Appropriate matrices should be easy to obtain, store and manipulate in standardized and reproducible measuring protocols at a reasonable cost.
Moreover, in most cases a single biomarker will not adequately represent the complexity of mechanisms underlying multifactorial diseases. In this regard, the generation of multidimensional biomarker panels displays a greater potential to identify valid markers. 5 The research efforts in asthma and allergic diseases during the last decades have focused on the identification of biomarkers applicable in clinical practice. Although several markers of allergic inflammation (e.g, IgE, eosinophilia, fractional exhaled nitric oxide [FENO])
have been described, their utility in diagnosis, prognosis and therapy is still controversial. [6] [7] [8] Different types of molecules (genes, metabolites, etc.) have been also proposed as biomarkers for allergic and chronic respiratory conditions. Some of them display good analytical
properties, but overall, they are insufficiently robust to be extrapolated to clinical practice. This fact partially arises from a paucity of clinical models for allergic diseases, which clearly constitutes a limiting factor in the search for biomarkers.
This review will summarize the biomarkers identified to date for allergic and chronic respiratory conditions, with special focus on those with higher clinical applicability.
| NEW METHODS TO IDENTIFY BIOMARKERS: TH E OMICS
The different omics characterize and quantify biological molecules, which share a common feature and which provide information about the structure and function of organisms. Omics are significantly contributing to the definition of disease endotypes and phenotypes and to the identification of therapeutic targets. Recent technological advances have pushed the omics field forward by allowing higher throughputs, improving detection limits and providing software tools to analyse and visualize the data.
Genomics, transcriptomics and epigenetics have been used to identify genes, RNA sub-types and DNA modifications, respectively.
Nevertheless, the validation of these observations requires the investigation of their functional consequences (e.g, the effect in transcription or splicing variants or in the functionality of proteins). Only this step permits valid conclusions for the underlying mechanisms of disease phenotypes ( Figure 1 ).
Metabolomics investigates the nature and concentration of the metabolites generated in living systems and is among the most recent approaches applied to allergy research. Metabolomics displays a high degree of versatility, as it is applicable to a great variety of matrices, whose nature can be tailored to the disease of interest. 4, 7 In chronic respiratory diseases, the metabolic analysis of exhaled breath condensate seems a promising matrix for biomarker identification. Other approaches which could help phenotype chronic airway conditions include electronic nose (eNose) or nuclear magnetic resonance-based metabolomics. 7 Nevertheless, the lack of standardized procedures for breath sampling, the effect of pH on some metabolites and the low concentrations are well-established limiting factors.
Individual omics display both strengths and weaknesses which overall define the validity and robustness of the results. The T A B L E 1 Characteristics of an ideal biomarker in asthma and allergy
The ideal biomarker
Supported by a body of evidence clarifying its biological significance Quantifiable in a cost-efficient analytical system with well-defined performance Detectable in a biological matrix obtained in an easy, rapid and costefficient way development of multi-omics and multi-matrix platforms in integrated approaches will probably provide a more holistic picture of biological situations, including allergic and chronic respiratory diseases. Nevertheless, the implementation of these advances in clinical practice requires the identification of biomarkers measurable in biological fluids obtained in an easy, rapid and cost-efficient way.
| UPPER AND LOWER AIRWAY DISEASES

| Rhinitis
Chronic rhinitis is generally divided into allergic rhinitis (AR) and non-allergic rhinitis (NAR). 9 The NAR category comprises a heterogeneous group of diseases mediated by immune or neurogenic mechanisms. 10 Conversely, AR is a relatively homogeneous entity arising from IgE-mediated inflammation. 11 Local allergic rhinitis (LAR) is a disease phenotype not fitting into the AR-NAR dichotomy. 12 The skin prick test (SPT) and/or serum allergen-specific (s)IgE and the nasal allergen challenge (NAC) positively identify AR patients. Subjects with LAR are defined by a positive NAC with negative SPT and serum sIgE, whereas NAR patients test negative for the three biomarkers.
Several inflammatory cells and mediators may also serve as diag- 16 A proportion of sIgE to total IgE >16.2%
predicted AIT success with 97.2% sensitivity and 88.1% specificity.
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In children, low serum osteopontin identifies responders to sublingual immunotherapy. 20 Serum osteopontin and basophil reactivity increase after NAC 21 and diminish following successful AIT. 16 Moreover, subcutaneous immunotherapy with HDM armed peripheral T regulatory cells with the ability to inhibit Th2 and Th9 proliferation. F I G U R E 1 Work-flow for the identification of biomarkers. 1: the clarification of disease mechanisms and the knowledge obtained from the clinical research and e-health records generates data about the diseases; 2: these data are interpreted by different disciplines and analysed using their corresponding methodology to generate hypothesis for disease-specific markers; 3: these potential markers need to be clinically validated in order to identify valid biomarkers and implement precision medicine display eosinophilic polyps. 23, 24 One study identified ten CRS clusters, of which six exhibited a type 2 inflammatory profile with raised IL-5 and eosinophilia. Type 2 clusters displayed a higher risk of nasal polyps and asthma. 25 The CRSwNP phenotype has been also associated with increased ILC2 at both the tissue level and peripheral blood. 26, 27 Several matrices have been used to predict CRS prognosis. Blood and tissue eosinophilia correlates with severity as measured by endoscopy and CT scan 28 and can predict recurrence following endoscopic sinus surgery. 23 In addition, a small study observed that programmed cell death-1 (PD-1) mRNA expression in nasal polyp tissue correlated with disease severity on CT scan, 29 while tissue gene expression of the eosinophil marker-Charcot-Leyden crystal protein-was associated with higher olfactory impairment. 30 The level of IL-5 and P-glycoprotein in nasal secretions helped to predict the olfactory and the CT scan scores, respectively. 31 Nasal nitric oxide (nNO) inversely correlated with CT scan-graded severity and increased after sinus surgery. 
| Asthma
Asthma phenotypes are classified into those displaying dominant type 2 inflammation, and those without significant type 2 inflammation, 33 with each group comprising a number of different diseases ( Figure 3 ).
Several biomarkers measurable in different matrices have been described for these asthma phenotypes. The relevance of asthma endotyping is perfectly illustrated by the case of the anti-IL-5 monoclonal antibody (mAb) mepolizumab whose initial lacklustre performance in unclassified asthma 34 was followed by excellent outcomes when administered to patients with eosinophilic asthma. 35 In any individual, the disease expression may be driven by com- 
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Environmental allergen down-regulated in severe asthma compared to healthy controls. 38 In a paediatric asthma cohort, the expression of five selected genes on CD4 lymphocytes (SRM, HDAC2, SLC33A1, P2RY10 and ADD3) predicted the atopic status with 100% sensitivity and 81.3% specificity, 39 while in another paediatric study, a fourteen-gene signature (MCEMP1, AQP9, PGLYRP1, S100P, RNASE2, OLFM4, CAMP, CEA-CAM8, LCN2, MPO, DEFA4, ELANE, BPI, DEFA1B, CTSG, HBD, ALAS2, RPS4Y2 and RPS4Y1) was unique to a neutrophilic phenotypic cluster. 40 In a recent pilot study, circulating blood microRNA profile (expressed as miRNA ratios) showed promise in differentiating allergic asthma from healthy controls. 41 Lipidomic profile and gene expression after low molecular weight hyaluronic acid stimulation of peripheral blood mononuclear cells were also shown to be different in severe asthma compared to mild asthma and healthy controls. 42 Peripheral differential cell counts can also serve as surrogate markers of airway inflammation. In a meta-analysis of 14 studies, the ability of blood eosinophils to predict airway eosinophilia showed an area under the curve (AUC) of 0.78. 43 Enumeration of peripheral ILC2 has a similar utility for predicting sputum eosinophilia. 44 Conversely, blood neutrophilia is less indicative of sputum neutrophilia, with an AUC of only 0.6. 45 The ex vivo response of blood neutrophils and eosinophils to stimulation with N-formyl-methionylleucyl-phenylalanine (fMLP), in combination with relevant clinical parameters, is also able to predict sputum eosinophilia. 
Staphylococcus aureus
| Serum mediators
The chitinase-like protein YKL-40 distinguished asthma from COPD and healthy controls. 47 Neutrophil expression of Siglec-9 is increased in patients with COPD and may have future potential to diagnose asthma. 48 Serum (soluble-cleaved) urokinase plasminogen-activated receptor (scuPAR) was found to be higher in severe, non-atopic asthma in a single study 49 and requires confirmation in further studies. Blood mediators can also predict airway inflammation. Overall, serum periostin moderately correlated with sputum eosinophilia. 50, 51 Eosinophilic cationic protein (ECP) is more predictive of sputum eosinophilia than serum IgE, 39 whereas C-reactive protein (CRP) is weakly associated with sputum neutrophilia. 57 as does nasal and pharyngeal EPX. 58 Importantly, nasal sampling may be particularly useful for patients in whom sputum induction is unsafe or not possible.
| Sputum cells and mediators
| Cellular bronchial samples
Patients in the UBIOPRED cohort could be divided into four groups based on the expression of nine gene sets in bronchial cells, each with mixed inflammatory patterns including one with concomitant Th2 and Th17 markers. 53 Interestingly, a different study found that Th2 and Th17 gene expression signatures were mutually exclusive in asthmatic airway tissue. 59 The authors sug- 
| Exhaled breath
The FENO displays an AUC of 0.8 for asthma diagnosis. 2 Of note, very high or low cut-offs for FENO can, respectively, rule-in or rule-out asthma. 27 Conversely, FENO has limited utility to predict sputum eosinophilia, 43 as it is confounded by corticosteroid treatment, atopy and smoking status. Volatile organic compounds (VOCs) in exhaled breath can be readily measured using eNose devices. Building on previous work which discriminates between COPD and asthma, eNose has identified label-free clinical and inflammatory clusters among asthma and COPD patients. 61 VOCs and other metabolites in exhaled breath can also differentiate asthma from healthy controls in adults and children. [62] [63] [64] [65] In a paediatric study, metabolomic analysis using nuclear magnetic reso- 
| Serum mediators
The stability of serum periostin over disease progression facilitates its use as a biomarker. 74 Elevated levels are associated with fixed and more severe airflow obstruction 75, 76 and greater longitudinal lung function decline. 77 Total serum IgE in children is associated with atopy, airway hyperresponsiveness (AHR) and bronchial wall thickening in CT scan. 69 In both adults and children, YKL-40 level correlates with severe asthma and poor lung function. 78, 79 The expression of ten selected microRNAs (HS_108.1, HS_112, HS_182.1, HS_240, HS_261.1, HS_3, HS_55.1, HS_91.1, hsa-miR-604 and hsa-miR-638) was higher in children with severe asthma. 
| Sputum cells and mediators
Sputum neutrophilia and ILC2 27 are associated with asthma severity. 81, 82 Changes in sputum eosinophilia reflect fluctuations in clinical asthma control. 83 Human tumour necrosis factor-like weak inducer of apoptosis (TWEAK) is an inflammatory mediator whose level in sputum correlated with higher severity, poor symptom control and decreased lung function in children with non-eosinophilic asthma. 
| Cellular bronchial samples
Bronchial neutrophilia is present in severe (compared to non-severe) asthma, independent of oral corticosteroid (OCS) intake. 85 Gene signatures analysed in endobronchial brushing and biopsy specimens predicted persistent airflow limitation in the UBIOPRED cohort. 86 In bronchoalveolar lavage samples, elevated CD4+ cells expressing both IL-4 and IL-17 predicted greater asthma severity.
69,87
| Exhaled breath
In both children and adults, FENO correlates with greater AHR, airway obstruction and exacerbations. 69, 88 Patients with FENO >45 ppb are at greater risk for suffering >2 asthma exacerbations/ EGUILUZ-GRACIA ET AL.
| 2295 year. 89 Electronic nose-measured VOCs predicted the loss of asthma control upon withdrawal of inhaled corticosteroids (ICS). 90 Reactive oxygen species (ROS) can also be detected in exhaled breath condensates of patients with asthma and has been shown to be suppressed by anti-inflammatory agents. 
| Functional imaging of lungs
Functional imaging with hyperpolarized gas magnetic resonance of the lung can predict asthma outcomes; persistent ventilation defects were associated with poorer asthma control. 92 Greater ventilation defects are also observed in patients with uncontrolled eosinophilic inflammation. 
94,95
Nevertheless, this finding was not reproduced in a real-life study. 96 There is a direct correlation between blood eosinophilia and the response to mepolizumab, 97 the anti-IL-5 receptor mAb benralizumab 98 and the anti-IL-4 receptor mAb dupilumab. 99 Blood eosinophilia may also predict and monitor the response to corticosteroids.
Atopic children with eosinophilia ≥300 cells/μL respond better to ICS. 100 A decrease in peripheral eosinophilia is observed with the up-dosing of ICS, 101 while titration of OCS to maintain blood eosinophilia <200 cells/μL improved asthma control. 
| Serum mediators
Elevated serum periostin predicts the response to omalizumab. 75, 103 Interestingly, total serum IgE does not predict the response to omalizumab, despite this molecule being not only the drug target, but also the basis for its dose calculation. 104 On the other hand, a reduction in serum-free IgE after 16-32 weeks on omalizumab is associated with a decrease in exacerbations over two years. 
| Sputum
Sputum eosinophilia ≥3% predicts response to corticosteroids 105 and mepolizumab. 35 Sputum eosinophilia as a guide for ICS therapy reduced exacerbations with no associated increase in the total ICS dose.
106,107
| Exhaled breath
In patients with symptoms suggestive of AHR, elevated FENO predicts response to ICS. 108 A systematic review concluded that using FENO to guide ICS therapy in adults reduced the mild but not the severe exacerbations. 109 Among children, FENO also showed unclear benefits on asthma outcomes. 110 A FENO level >19.5 ppb also correlated with response to omalizumab. 75 
| Urine
Urine bromotyrosine correlates with corticosteroid responsiveness, and the predictive accuracy further improves when combined with high FENO levels. 94 Despite the previous enumeration being made in a matrix-related fashion, the complexity of most asthma phenotypes will require multidimensional approaches to identify valid biomarkers ( Table 2 ). This aspect is exemplified by the greatest benefit from dupilumab being observed in asthma patients exhibiting both elevated peripheral eosinophilia and FENO. 99 
| FOOD ALLERGY AND ANAPHYLAXIS
The food allergy (FA) phenotypes differ on their IgE dependence and prognosis ( Figure 4 ). 111 Given this heterogeneity, the search for FA biomarkers has gained significant attention. 
| IgE-mediated food allergy
The identification of children at risk of developing FA might help establish preventive strategies. 112 The balance between type 2 and type 1 chemokines in cord blood influenced the sensitization to food allergens at the age of 3 years in children from Taiwan. 113 117 Basophil activation test (BAT) might also correlate with the OFC outcome in food-dependent NSAID-induced anaphylaxis. 118 Anaphylaxis is the most severe phenotype of IgE-mediated hypersensitivity, and the increase in serum tryptase is a helpful biomarker in most cases. 119 In Canadian children, milk was the food most likely to increase serum tryptase levels. 119 Interestingly, the combination of the serum levels of apolipoprotein A1 and the prostaglandin D2 metabolite 9α,11β-PGF2, displayed a good diagnostic performance for food-induced anaphylaxis in German patients.
120
T A B L E 2 Summary of biomarkers for diagnosis, prognosis and response prediction and monitoring in asthma Determine atopy status
• scuPAR Inflammatory phenotyping
Airway remodelling
• IgE Asthma severity
Predict response to omalizumab 
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Oral immunotherapy (OIT) is a promising tool for persistent forms of IgE-mediated FA. 111, [121] [122] [123] In anaphylactic children from the United States, successful milkOIT induced the increase in peripheral invariant natural killer T (iNKT) cells and skewed milk-stimulated iNKT cells from a type 2 to a type 1 profile. 124 Furthermore, successful OIT reduced blood eosinophils and increased several mediators functionally related to type 1 immunity (adipokines, leptin or resistin) in milk-allergic children from Finland. 125 A higher baseline sIgA and a rapid increase in sIgG1 after OIT initiation identified good responder egg-allergic children from Japan. 126 The adverse reactions (AdR) during OIT limit its use in the clinics. 123 In children undergoing peanutOIT, the presence of allergic rhinitis and the SPT wheal size were associated with systemic and gastrointestinal AdR. 127 Adjuvant therapy with omalizumab might reduce AdR during OIT, 123 and the combination of basophil reactivity and sIgE/total IgE ratio at baseline could identify patients more likely to benefit from omalizumab during milkOIT. 128 Beyond the oral route, other administration routes are under investigation for severe FA. 123 Sublingual immunotherapy
Diagnosis Prognosis
Response prediction and monitoring
Urine Distinguish asthma from COPD
• Metabolites
Inflammatory phenotyping
• Urine metabolites Predict response to corticosteroids
• Urine bromotyrosine COPD, chronic obstructive pulmonary disease; CRP, C-reactive protein; ECP, eosinophilic cationic protein; eNose, electronic Nose; EPX, eosinophil peroxidase; FENO, fractional exhaled nitric oxide; fMLF, N-formyl-methionyl-leucyl-phenylalanine; ICS, inhaled corticosteroid; IgE, immunoglobulin E; IL-5, interleukin-5; ILC2, group 2 innate lymphoid cell; LTE4, leukotriene 4; MPO, myeloperoxidase; NERD, aspirin-exacerbated respiratory disease; scuPAR, serum soluble-cleaved form of the urokinase plasminogen-activated receptor; Siglec-9, sialic acid-binding immunoglobulin-type lectins-9; TWEAK, tumour necrosis factor-like weak inducer of apoptosis; VOC, volatile organic compounds.
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| Other types of food allergy
The diagnosis of eosinophilic esophagitis requires the demonstration of >15 eosinophils/high-power field in the oesophagus of individuals with suggestive symptoms. 131 Oesophageal eosinophilia correlated with male gender and the number of positive food sIgE tests in American children. 132 This observation might help to limit the number of endoscopies required for diagnosis. 131 The management of food protein-induced enterocolitis syndrome (FPIE) patients involves consecutive OFCs to asses for disease resolution. 133 In Japanese children with FPIES, the OFCs induced the activation of intestinal and peripheral eosinophils. 134 Interestingly, the peripheral level of Creactive protein and of eosinophilia correlated with a poor and good prognosis, respectively, in Japanese patients with FPIES. 135 Despite the progress made in recent years, most biomarkers remain to be validated in larger populations and distinct geographical areas. Moreover, growing evidence suggests that airway allergy influences many of the parameters identified as FA biomarkers. 136, 137 In this regard, the clarification of atopic phenotypes and their relationship with FA will improve the interpretation of biomarkers.
68,138
| DRUG HYPE RSE NSITIVITY
A summary of the different drug hypersensitivity phenotypes can be seen in Figure 5 . 
| Cross-intolerance to NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) are the most common triggers of drug hypersensitivity reactions, and in most cases, these reactions are not mediated by immunological mechanisms.
139
In non-selective or cross-intolerant reactions, NSAIDs from different groups provoke skin or respiratory symptoms. 140 In these cases, the reaction-inducing potential does not rely on the chemical structure of the drug, but on its COX-1 inhibitory activity. 140 Aspirin-or NSAID-exacerbated respiratory disease (AERD and NERD, respectively) is the most studied phenotype of cross-intolerance. This entity is defined by the onset of respiratory symptoms upon intake of NSAIDs and is related to a dysregulation of arachidonic acid (AA) metabolism with overproduction of leukotrienes (LT) and prostaglandins (PG). 141 Many NERD subjects have concomitant CRS and asthma. 141 In a Korean study, NERD patients were divided into four sub-phenotypes based on the presence of CRS, urticaria and atopy. 142 Interestingly, significant differences existed in asthma severity, total serum IgE, sputum and peripheral eosinophilia, and urinary LTE4 (uLTE4). 142 In American patients, uLTE4 helped to identify aspirin sensitivity in patients with different nasal inflammatory conditions. 143 A recent meta-analysis reported that the sensitivity and specificity of uLTE4 for identifying aspirin sensitivity in asthma ranged from 0.55 to 0.81 and from 0.77 to 0.82, respectively, depending on the detection method. 144 Serum LTE4 in combination with LTE4/PGF2α ratio might help to detect NERD among other asthma phenotypes. 145 Aspirin provocation increased 8-iso-PGE2 in the exhaled breath condensate of NERD patients and correlated with uLTE4. 146 Platelet activation was also associated with overproduction of AA metabolites and to a reduced lung function in NERD patients. 147 Other biomarkers beyond AA metabolites have been related to NERD. The serum sphingosine-1-phosphate was higher in NERD patients than in other asthmatics. 148 American patients with NERD displayed higher activation of mast cells, basophils and platelets measured in nasal microparticles than other CRS individuals. 149 Overall, these biomarkers might facilitate the diagnosis of NSAID hypersensitivity by decreasing the need for drug provocations. Some cross-intolerance phenotypes resolve over time, 150 and these biomarkers might help determine the most adequate timing to test for aspirin tolerance.
| Immune-mediated reactions
These conditions can be divided into immediate and non-immediate reactions arising from IgE-and T cell-mediated mechanisms, respectively ( Figure 5 ). 
| Betalactams
Skin testing displays a diagnostic sensitivity of up to 70%. 151 Available in vitro tests include immunoassays to quantify serum BL-sIgE, including the commercial ImmunoCAP© (Thermo-Fisher, Uppsala, Sweden). 151 Its sensitivity shows a high variability (0%-50%), 152 depending on the reaction severity and the time gap at the moment of measurement. 153 Moreover, ImmunoCAP© can induce false-positive results when testing for Penicillin-V. 154 Increased serum tryptase during the acute phase of reactions can confirm mast cell activation 112 and correlates with the severity. 155 The sensitivity of BAT for BL allergy ranges from 22% to 55% with a specificity of up to 96%.
156,157
| Fluoroquinolones
Skin testing is not useful for the diagnosis of FQ allergy, 158 and there are no available immunoassays. The CD63-based BAT displayed 83.3% sensitivity and 88.9% specificity for ciprofloxacin allergy. 159 Surprisingly, CD203c outperforms CD63 as BAT-activation marker for moxifloxacin allergy, yet its sensitivity was low (36.4%). 159, 160 These data question the role of basophils in moxifloxacin allergy, but identify BAT as a promising tool for ciprofloxacin allergy.
| Non-immediate reactions
Patch testing and intradermal test with delayed reading are useful in vivo biomarkers. The sensitivity of the in vitro lymphocyte transformation test (LTT) is lower than that of BAT for immediate reactions. 63, 155 A combination of granzyme B and granulysin expression in blood cells can detect lymphocyte activation in the setting of severe cutaneous reactions like Stevens-Johnson syndrome. 161 The screening for HLAB*57:01 before abacavir prescription is recommended by regulatory agencies, 162 as it showed 100% of negative predictive value for immunologically confirmed abacavir hypersensitivity. 163 The screening for HLAB*15:02 is also recommended before carbamazepine treatment in patients at high risk (Han Chinese, Vietnamese, Cambodians, etc.). This search will be a long and resource-consuming path requiring large population cohorts. Among the different disciplines applied to biomarker identification, metabolomics appears as a promising tool, yet growing evidence indicates that valid biomarkers will be detected by multidimensional strategies. Valid biomarkers do not only need to accurately reflect the phenotype-specific disease mechanisms, but also to be quantifiable in a rapid, easy and cost-efficient way. Only under these premises, the research in biomarker identification will be able to impact the clinical practice and translate into an improved diagnosis, management, and treatment of patients with allergic and chronic respiratory diseases.
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